[Comparison of effect of norepinephrine and terlipressin on patients with ARDS combined with septic shock: a prospective single-blind randomized controlled trial]

What Was Tested

Researchers studied Terlipressin in this randomized controlled trial publication.

To approach the effect of different vasopressor on hemodynamics, volume responsiveness, fluid volume balance, renal function and prognosis in patients with acute respiratory distress syndrome (ARDS) complicated with septic shock.

Who Took Part

ARDS patients with septic shock admitted to the Department of Critical Care Medicine of Jiangxi Provincial People's Hospital from January 1st, 2015 to May 1st, 2016 were enrolled.

The patients satisfied ARDS Berlin diagnostic criteria, over 15 years old, needing vasopressor after fluid resuscitation were enrolled.

How the Study Was Run

In design terms this was a randomized and single-blind study.

The participants were allocated by chance, so the Terlipressin group and the comparison group should start out alike.

In this single-blind Terlipressin study one party knew the assignments and the other did not.

The methods mention a period of 15 years.

A prospective single-blind randomized controlled trial was conducted.

The patients were divided into norepinephrine group (NE group) and terlipressin group (TP group) by randomise number table derived by computer.

Hemodynamics and extravascular lung water index (EVLWI) were monitored by pulse indicator continuous cardiac output (PiCCO).

The differences in hemodynamics, EVLWI, oxygenation index (OI), lactate clearance rate (LCR), rate of positive volume responsiveness, urinary output, fluid volume balance, renal function, and prognostic indicators were compared between the two groups.

What Was Measured

Topics PubMed links to this paper include Berlin, Hemodynamics, Lypressin, Norepinephrine, Respiratory Distress Syndrome, Shock, Septic and Terlipressin.

What This Means in Plain Language

The paper is a randomized and single-blind study of Terlipressin over 15 years.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Zhonghua wei zhong bing ji jiu yi xue), a journal based in China.

More context: the Terlipressin compound page, all human trials.